Modality
Cell Therapy
MOA
HER2
Target
EGFR
Pathway
Amyloid
Endometrial CaRA
Development Pipeline
Preclinical
~Apr 2013
→ ~Jul 2014
Phase 1
~Oct 2014
→ ~Jan 2016
Phase 2
~Apr 2016
→ ~Jul 2017
Phase 3
~Oct 2017
→ ~Jan 2019
NDA/BLA
Apr 2019
→ Sep 2029
NDA/BLACurrent
NCT08215525
1,257 pts·RA
2019-04→2029-09·Recruiting
1,257 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-09-053.4y awayPh3 Readout· RA
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2029-09-05 · 3.4y away
RA
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08215525 | NDA/BLA | RA | Recruiting | 1257 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR | |
| Voxaderotide | Viking Therapeutics | Approved | PD-L1 | |
| Adagrarapivir | Ideaya Bio | Phase 1/2 | IL-17A |